cardiovascular prevention - antiplatelets drug - all type of patients clinical trials results meta-analysis

<h1> <a href="TM4-2-antiplatelets drug-cardiovascular prevention" > <strong>cardiovascular prevention</strong> - antiplatelets drug </a> - all type of patients trial results systematic overview and meta-analysis </h1> <h2>Main characteristics of the included studies</h2> <table> <tr> <th>Trial</th> <th>Treatments</th> <th>Patients</th> <th>Methods</th> </tr> <tr> <td> <a href="../TRC_t4257.htm"> British Doctor’s Trial, 1988 </a> <br> </td> <td> aspirin 500 mg/d<br>  <i>versus</i> <br> no aspirin </td> <td> apparently healthy male doctors </td> <td> follow-up 5.5 years<br> n=3429/1710<br> Parallel groups<br> open <br> UK </td> </tr> <tr> <td> <a href="../TRC_t4258.htm"> Physicians Health Study, 1989 </a> <br> NCT00000500 </td> <td> aspirin 325 mg every other day<br>  <i>versus</i> <br> placebo </td> <td> Healthy men </td> <td> follow-up 60.2 months<br> n=11037/11034<br> Parallel groups<br> double blind <br> </td> </tr> <tr> <td> <a href="../TRC_t4259.htm"> Thrombosis Prevention Trial, 1998 </a> <br> NCT00000614 </td> <td> aspirin 75 mg/d (controlled release)<br>  <i>versus</i> <br> placebo </td> <td> Men at high risk of CHD </td> <td> follow-up median 6.8y<br> n=2545/2540<br> Factorial plan<br> double blind <br> UK </td> </tr> <tr> <td> <a href="../TRC_t4260.htm"> HOT, 1998 </a> <br> </td> <td> aspirin 75 mg daily<br>  <i>versus</i> <br> placebo </td> <td> patients aged 50-80 with hypertension and diastolic blood pressure between 100 mmHG and 115 mmHG </td> <td> follow-up mean 3.8 y (range 3.3-4.9y)<br> n=9399/9391<br> Factorial plan<br> Double blind <br> Europe, North and South America, and Asia </td> </tr> <tr> <td> <a href="../TRC_t4261.htm"> Primary Prevention Project, 2001 </a> <br> </td> <td> aspirin 100 mg/d<br>  <i>versus</i> <br> no aspirin (open control) </td> <td> men and women aged 50 years or greater, with at least one of the major recognised cardiovascular risk factors. </td> <td> follow-up 3.6 y<br> n=2226/2269<br> Factorial plan<br> Open <br> Italy </td> </tr> <tr> <td> <a href="../TRC_t4366.htm"> CAPRIE, 1996 </a> <br> </td> <td> clopidogrel 75 mg once daily<br>  <i>versus</i> <br> aspirin 325 mg once daily </td> <td> patients with atherosclerotic vascular disease manifested as either recent ischaemic stroke, recent myocardial infarction, or symptomatic peripheral arterial disease </td> <td> follow-up mean 1.91 years<br> n=9599/9586<br> Parallel groups<br> Double blind <br> 16 countries </td> </tr> <tr> <td> <a href="../TRC_t4367.htm"> CHARISMA, 2006 </a> <br> NCT00050817 </td> <td> clopidogrel (75 mg per day) plus low-dose aspirin (75 to 162 mg per day)<br>  <i>versus</i> <br> placebo plus low-dose aspirin </td> <td> patients with either clinically evident cardiovascular disease or multiple risk factors </td> <td> follow-up median 28 months<br> n=7802/7801<br> Parallel groups<br> Double blind <br> 32 countries </td> </tr> <tr> <td> <a href="../TRC_t4691.htm"> Women’s Health Study, 2005 </a> <br> </td> <td> aspirin 100mg daily<br>  <i>versus</i> <br> placebo </td> <td> initially healthy women 45 years of age or older </td> <td> follow-up 10.1 y mean (range 8.2 to 10.9<br> n=19934/19942<br> Factorial plan<br> Double blind <br> </td> </tr> <tr> <td> <a href="../TRC_t9895.htm"> AAA, 2009 </a> <br> ISRCTN66587262 </td> <td> aspirin 100mg daily<br>  <i>versus</i> <br> placebo </td> <td> men and women aged 50 to 80 years with asymptomatic atherosclerosis detected by low ankle brachial index (<=0.95) </td> <td> follow-up 8.2 y (mean)<br> n=1675/1675<br> Parallel groups<br> double blind <br> UK, Scotland </td> </tr> <tr> <td> <a href="../TRC_t12048.htm"> TRA-2P TIMI 50, 2012 </a> <br> NCT00526474 </td> <td> vorapaxar (SCH 530348) 2.5-mg daily<br>  <i>versus</i> <br> placebo (added to the existing standard of care for preventing heart attack and stroke (eg, aspirin, clopidogrel) </td> <td> patients with a known history of atherosclerosis (MI, ischemic stroke, or peripheral vascular disease) </td> <td> follow-up 2.5 y (median)<br> n=13225/13244<br> Parallel groups<br> double-blind <br> </td> </tr> <tr> <td> <a href="../TRC_t10573.htm"> JPPP, </a> <br> NCT00225849 </td> <td> aspirin<br>  <i>versus</i> <br> no aspirin </td> <td> Japanese patients aged 60 to 85 years with hypertension, dyslipidemia, or diabetes mellitus </td> <td> follow-up <br> n=-9/-9<br> Parallel groups<br> open <br> Japan </td> </tr> </table> <h2>References</h2> <p> <b>British Doctor’s Trial, 1988 : </b> Peto R, Gray R, Collins R, Wheatley K, Hennekens C, Jamrozik K, Warlow C, Hafner B, Thompson E, Norton SRandomised trial of prophylactic daily aspirin in British male doctors. <i>Br Med J (Clin Res Ed) 1988 Jan 30;296:313-6</i> [PMID 3125882] </p> <p> <b>Physicians Health Study, 1989 : </b> Final report on the aspirin component of the ongoing Physicians' Health Study. Steering Committee of the Physicians' Health Study Research Group. <i>N Engl J Med 1989 Jul 20;321:129-35</i> [PMID 2664509] </p> <p> <b>Thrombosis Prevention Trial, 1998 : </b> Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. The Medical Research Council's General Practice Research Framework. <i>Lancet 1998 Jan 24;351:233-41</i> [PMID 9457092] </p> <p> <b>Thrombosis Prevention Trial, 1998 : </b> Meade TW, Wilkes HC, Stirling Y, Brennan PJ, Kelleher C, Browne WRandomized controlled trial of low dose warfarin in the primary prevention of ischaemic heart disease in men at high risk: design and pilot study. <i>Eur Heart J 1988;9:836-43</i> [PMID 3053176] </p> <p> <b>HOT, 1998 : </b> Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, Menard J, Rahn KH, Wedel H, Westerling SEffects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. <i>Lancet 1998 Jun 13;351:1755-62</i> [PMID 9635947] </p> <p> <b>HOT, 1998 : </b> Hansson L, Zanchetti AThe Hypertension Optimal Treatment (HOT) Study--patient characteristics: randomization, risk profiles, and early blood pressure results. <i>Blood Press 1994;3:322-7</i> [PMID 7866597] </p> <p> <b>Primary Prevention Project, 2001 : </b> de Gaetano GLow-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Collaborative Group of the Primary Prevention Project. <i>Lancet 2001 Jan 13;357:89-95</i> [PMID 11197445] </p> <p> <b>CAPRIE, 1996 : </b> A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. <i>Lancet 1996 Nov 16;348:1329-39</i> [PMID 8918275] </p> <p> <b>CHARISMA, 2006 : </b> Bhatt DL, Fox KA, Hacke W, Berger PB, Black HR, Boden WE, Cacoub P, Cohen EA, Creager MA, Easton JD, Flather MD, Haffner SM, Hamm CW, Hankey GJ, Johnston SC, Mak KH, Mas JL, Montalescot G, Pearson TA, Steg PG, Steinhubl SR, Weber MA, Brennan DM, Fabry-RibClopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. <i>N Engl J Med 2006;354:1706-17</i> [PMID 16531616] 10.1056/NEJMoa060989 </p> <p> <b>Women’s Health Study, 2005 : </b> Ridker PM, Cook NR, Lee IM, Gordon D, Gaziano JM, Manson JE, Hennekens CH, Buring JEA randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. <i>N Engl J Med 2005 Mar 31;352:1293-304</i> [PMID 15753114] </p> <p> <b>Women’s Health Study, 2005 : </b> Rexrode KM, Lee IM, Cook NR, Hennekens CH, Buring JEBaseline characteristics of participants in the Women's Health Study. <i>J Womens Health Gend Based Med 2000;9:19-27</i> [PMID 10718501] 10.1089/152460900318911 </p> <p> <b>JPAD DOUBLON à effacer, 2008 : </b> Ogawa H, Nakayama M, Morimoto T, Uemura S, Kanauchi M, Doi N, Jinnouchi H, Sugiyama S, Saito YLow-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. <i>JAMA 2008;300:2134-41</i> [PMID 18997198] </p> <p> <b>AAA, 2009 : </b> Fowkes FG, Price JF, Stewart MC, Butcher I, Leng GC, Pell AC, Sandercock PA, Fox KA, Lowe GD, Murray GDAspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial. <i>JAMA 2010 Mar 3;303:841-8</i> [PMID 20197530] 10.1001/jama.2010.221 </p> <p> <b>JPPP, : </b> Teramoto T, Shimada K, Uchiyama S, Sugawara M, Goto Y, Yamada N, Oikawa S, Ando K, Ishizuka N, Yamazaki T, Yokoyama K, Murata M, Ikeda YRationale, design, and baseline data of the Japanese Primary Prevention Project (JPPP)-a randomized, open-label, controlled trial of aspirin versus no aspirin in patients with multiple risk factors for vascular events. <i>Am Heart J 2010;159:361-369.e4</i> [PMID 20211296] 10.1016/j.ahj.2009.11.030 </p> <p> <b>TRA-2P TIMI 50, 2012 : </b> Morrow DA, Scirica BM, Fox KA, Berman G, Strony J, Veltri E, Bonaca MP, Fish P, McCabe CH, Braunwald EEvaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2 degrees P)-TIMI 50 trial. <i>Am Heart J 2009 Sep;158:335-341.e3</i> [PMID 19699854] </p> <p> <b>TRA-2P TIMI 50, 2012 : </b> Morrow DA, Braunwald E, Bonaca MP, Ameriso SF, Dalby AJ, Fish MP, Fox KA, Lipka LJ, Liu X, Nicolau JC, Oude Ophuis AJ, Paolasso E, Scirica BM, Spinar J, Theroux P, Wiviott SD, Strony J, Murphy SAVorapaxar in the Secondary Prevention of Atherothrombotic Events. <i>N Engl J Med 2012 Mar 24;:</i> [PMID 22443427] 10.1056/NEJMoa1200933 </p>